Evidence map›Paper›PMID 34464516›Full record

ArticleCancer medicine2021

The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.

Massimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, Elisabetta Abruzzese, Gianni Binotto, Luigi Scaffidi, Maddalena Cordioli, Daniela Damiani, Eros Di Bona, Malgorzata Monika Trawinska and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Massimiliano BonifacioDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.ORCID 0000-0003-0716-1686
Mario TiribelliDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.ORCID 0000-0001-9449-2621
Maria Cristina MiggianoHematology Department, San Bortolo Hospital, Azienda ULSS8 "Berica" of Vicenza, Vicenza, Italy.
Elisabetta AbruzzeseHematology, S. Eugenio Hospital, ASL Roma2, Tor Vergata University, Rome, Italy.ORCID 0000-0001-5228-6491
Gianni BinottoPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Luigi ScaffidiDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Maddalena CordioliDepartment of Diagnostics and Public Health, Section of Infectious Diseases, University of Verona, Verona, Italy.
Daniela DamianiDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.ORCID 0000-0002-1663-4468
Eros Di BonaHematology Department, San Bortolo Hospital, Azienda ULSS8 "Berica" of Vicenza, Vicenza, Italy.
Malgorzata Monika TrawinskaHematology, S. Eugenio Hospital, ASL Roma2, Tor Vergata University, Rome, Italy.
Ilaria TanasiDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Maria Vittoria DubbiniDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
Vanessa VelottaHematology, S. Eugenio Hospital, ASL Roma2, Tor Vergata University, Rome, Italy.
Giulia CeccarelliHematology, S. Eugenio Hospital, ASL Roma2, Tor Vergata University, Rome, Italy.
Elisabetta PierdomenicoPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Mariella Lo SchiricoPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Gianpietro SemenzatoPadua School of Medicine, Department of Medicine, Hematology and Clinical Immunology, Padua, Italy.
Marco RuggeriHematology Department, San Bortolo Hospital, Azienda ULSS8 "Berica" of Vicenza, Vicenza, Italy.
Renato FaninDivision of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
Evelina TacconelliDepartment of Diagnostics and Public Health, Section of Infectious Diseases, University of Verona, Verona, Italy.
Giovanni PizzoloDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Mauro KramperaDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
University of Verona · ITASL Roma · ITUniversity of Padua · ITUniversity of Udine · ITOspedale San Bortolo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with hematological malignancies are at an increased risk of SARS-CoV-2 disease (COVID-19) and adverse outcome. However, a low mortality rate has been reported in patients with chronic myeloid leukemia (CML). Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a protective role against severe COVID-19.

methodsWe conducted a cross-sectional study of 564 consecutive patients with CML who were tested for anti-SARS-CoV-2 IgG/IgM antibodies at their first outpatient visit between May and early November 2020 in five hematologic centers representative of three Italian regions.

resultsThe estimated serological prevalence of SARS-CoV-2 infection in patients with CML after the first pandemic wave was similar to that in the general population (about 2%), both at national and regional levels. CML patients with positive anti-SARS-CoV-2 serology were more frequently male (p = 0.027) and active workers (p = 0.012), while there was no significant association with TKI treatment type. Only 3 out of 11 IgG-positive patients had previously received a molecular diagnosis of COVID-19, while the remainders were asymptomatic or with mild symptoms.

conclusionsOur data confirm that the course of SARS-CoV-2 infection in patients with CML is generally mild and reassure about the safety of continuing TKIs during the COVID-19 pandemic. Furthermore, we suggest that patients with CML succeed to mount an antibody response after exposure to SARS-CoV-2, similar to the general population.

Indexed as

AdultAgedAged, 80 and overCOVID-19COVID-19 Serological TestingCross-Sectional StudiesFemaleHumansImmunoglobulin GImmunoglobulin MItalyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPrevalenceSARS-CoV-2Immunoglobulin GImmunoglobulin Mchronic myeloid leukemiaCOVID-19prevalenceserological testsTKIs

Identifiers

PMID34464516
PMCPMC8446554
OpenAlexW3196870661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.